4-hydrazinopyrido<3,4-d>pyridazine-1(2H)-one | 87544-88-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-hydrazinopyrido<3,4-d>pyridazine-1(2H)-one
• 英文别名: 4-hydrazinopyrido[3,4-d]pyridazine-1(2H)-one；4-hydrazinyl-2H-pyrido[3,4-d]pyridazin-1-one
• CAS: 87544-88-5
• 化学式: C₇H₇N₅O
• mdl: MFCD19201759
• 分子量: 177.165
• InChiKey: RYRZAEOZLXMOLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-hydrazinopyrido<3,4-d>pyridazine-1(2H)-one 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.33h， 生成 3-(4'-carbamoylpyrid-3'-yl)-5,6-bis-methoxycarbonylthiazolo[2,3-c][1,2,4]triazole
  参考文献：
  名称：

  Novel ring transformations of condensed [1,2,4]triazolo[4,3-b]pyridazine-6(5H)-one-3(2H)-thiones effected by dialkyl-acetylenedicarboxylates

  摘要：

  On heating with dialkyl-acetylenedicarboxylates in DMF condensed [1,2,4]-triazolo[4,3-b] pyridazine-6(5H)-one-3(2H)-thiones undergo unprecedented ring transformations yielding novel tetracyclic 1,3-diazepines and thiazolotriazole derivatives depending on the applied reaction temperature. The observed substrate selectivity was interpreted on the basis of the results of comparative theoretical calculations carried out at semiempirical level (AMI). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(01)00672-x
• 作为产物：
  描述：

  4-chloropyrido[3,4-d]pyridazin-1(2H)-one 在 一水合肼 作用下， 以97.1%的产率得到4-hydrazinopyrido<3,4-d>pyridazine-1(2H)-one
  参考文献：
  名称：

  Koermendy, K.; Kovacs, T.; Ruff, F., Acta Chimica Hungarica, 1983, vol. 112, # 4, p. 487 - 500

  摘要：

  DOI：

文献信息

• TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
  申请人：HADDACH Mustapha

  公开号：US20110065712A1

  公开（公告）日：2011-03-17

  The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.

  本发明提供了抑制CK2和/或Pim激酶的化合物和含有这些化合物的组合物。这些三环化合物及其含量有用于治疗增殖性疾病，如癌症，以及其他激酶相关疾病，包括炎症，疼痛，病原体感染和某些免疫性疾病。
• KOERMENDY, K.;KOVACS, T.;RUFF, F.;KOEVESDI, I., ACTA CHIM. HUNG., 1983, 112, N 4, 487-499
  作者：KOERMENDY, K.、KOVACS, T.、RUFF, F.、KOEVESDI, I.

  DOI：——

  日期：——
• Novel ring transformations of condensed [1,2,4]triazolo[4,3-b]pyridazine-6(5H)-one-3(2H)-thiones effected by dialkyl-acetylenedicarboxylates
  作者：Mónika Simó、Antal Csámpai、Veronika Harmat、Orsolya Barabás、Gábor Magyarfalvy

  DOI：10.1016/s0040-4020(01)00672-x

  日期：2001.8

  On heating with dialkyl-acetylenedicarboxylates in DMF condensed [1,2,4]-triazolo[4,3-b] pyridazine-6(5H)-one-3(2H)-thiones undergo unprecedented ring transformations yielding novel tetracyclic 1,3-diazepines and thiazolotriazole derivatives depending on the applied reaction temperature. The observed substrate selectivity was interpreted on the basis of the results of comparative theoretical calculations carried out at semiempirical level (AMI). (C) 2001 Elsevier Science Ltd. All rights reserved.
• Koermendy, K.; Kovacs, T.; Ruff, F., Acta Chimica Hungarica, 1983, vol. 112, # 4, p. 487 - 500
  作者：Koermendy, K.、Kovacs, T.、Ruff, F.、Koevesdi, I.

  DOI：——

  日期：——